About this trial
Cancer treatments can have long-term effects on fertility. In men, scientific studies suggest that the process of sperm formation (spermatogenesis) may be disrupted even years after recovery, with potential consequences not only for fertility but also for the health of offspring. The effects of chemotherapy on sperm quality, particularly on DNA packaging (chromatin) and the epigenome, remain poorly understood. Therefore, further in-depth studies are needed to determine whether a history of cancer and chemotherapy treatment may impact the health of children fathered by young male survivors.
We therefore propose to conduct a clinical study aimed at better understanding the mechanisms by which chemotherapies affect spermatogenesis. The results could provide answers by identifying the effects of these drugs on the fertility of young male cancer patients in the long term and the sperm epigenome indicative of the health of the progeny.
Eligibility criteria
Qualifiers
Men aged 18 to 45 years
Diagnosed with Hodgkin lymphoma
Treatment-naïve to any cytotoxic therapy
Whose treatment regimen consists of 4 to 6 cycles of ABVD or BrECADD
Disqualifiers
Patient receiving abdominal radiotherapy
Trial design
Treatments tested in this trial
- Additional semen samples
Treatment groups
Sponsors and collaborators
Rennes University Hospital
Lead sponsor
Institut National de la Recherche Scientifique - Centre Armand Frappier Santé Biotechnologie
Collaborator